Literature DB >> 26350197

Diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with radiotherapy.

Giancarlo Iannelli1, Rocchina Caivano1, Luciana Rago1, Vittorio Simeon1, Antonella Lotumolo1, Paola Rabasco1, Antonio Villonio1, Matilde Gioioso1, Pietro Mastrangelo1, Flavio Barchetti2, Valeria Panebianco2, Luca Macarini3, Giuseppe Guglielmi3,4, Aldo Cammarota1.   

Abstract

AIMS: To evaluate the utility of a multiparametric 3T magnetic resonance imaging (MRI) study using diffusion-weighted images (DWI) for the assessment of prostate cancer before and after radiotherapy (RT).
METHODS: A total of 34 patients, who received a histologic diagnosis of prostate adenocarcinoma, underwent MRI examination before and after local RT for the assessment of response to treatment. Apparent diffusion coefficient (ADC) values were calculated and compared.
RESULTS: Before RT, DWI shows pathologic restriction of signal, while after RT pathologic restriction of signal was reduced or disappeared. The ADC values were significantly increased after therapy (p<0.05).
CONCLUSIONS: The use of DWI with ADC measurements may be an imaging biomarker in the assessment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26350197     DOI: 10.5301/tj.5000415

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  2 in total

1.  Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.

Authors:  Daniel T Oberlin; David D Casalino; Frank H Miller; Richard S Matulewicz; Kent T Perry; Robert B Nadler; Shilajit Kundu; William J Catalona; Joshua J Meeks
Journal:  Urology       Date:  2016-03-07       Impact factor: 2.649

2.  Predictive Value of Early Response to Chemoradiotherapy in Advanced Esophageal Squamous Cell Carcinoma by Diffusion-Weighted MR Imaging.

Authors:  Wei Chen; Ya-Ting Wang; Lili Guo; Zhaohuan Zhu; Hai-Fei Zhou; Genji Bai
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.